company background image
BNTC

Benitec Biopharma NasdaqCM:BNTC Stock Report

Last Price

US$1.16

Market Cap

US$9.5m

7D

56.8%

1Y

-72.6%

Updated

30 Jun, 2022

Data

Company Financials +
BNTC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BNTC Stock Overview

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines.

Benitec Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Benitec Biopharma
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$4.78
52 Week LowUS$0.74
Beta1.6
1 Month Change10.48%
3 Month Change-49.12%
1 Year Change-72.58%
3 Year Change-89.24%
5 Year Change-96.07%
Change since IPO-99.66%

Recent News & Updates

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

BNTCUS BiotechsUS Market
7D56.8%3.8%1.6%
1Y-72.6%-25.8%-20.8%

Return vs Industry: BNTC underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: BNTC underperformed the US Market which returned -20.8% over the past year.

Price Volatility

Is BNTC's price volatile compared to industry and market?
BNTC volatility
BNTC Average Weekly Movement23.2%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: BNTC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: BNTC's weekly volatility has increased from 14% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199514Jerel Bankshttps://benitec.com

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

Benitec Biopharma Fundamentals Summary

How do Benitec Biopharma's earnings and revenue compare to its market cap?
BNTC fundamental statistics
Market CapUS$9.48m
Earnings (TTM)-US$17.14m
Revenue (TTM)US$75.00k

126.5x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNTC income statement (TTM)
RevenueUS$75.00k
Cost of RevenueUS$1.00k
Gross ProfitUS$74.00k
Other ExpensesUS$17.22m
Earnings-US$17.14m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.10
Gross Margin98.67%
Net Profit Margin-22,858.67%
Debt/Equity Ratio0%

How did BNTC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BNTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNTC?

Other financial metrics that can be useful for relative valuation.

BNTC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.9x
Enterprise Value/EBITDA-0.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does BNTC's PB Ratio compare to its peers?

BNTC PB Ratio vs Peers
The above table shows the PB ratio for BNTC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.5x
PHIO Phio Pharmaceuticals
0.5x117.9%US$9.9m
WINT Windtree Therapeutics
0.4x23.1%US$12.3m
CYCC Cyclacel Pharmaceuticals
0.4x-14.7%US$14.8m
GLMD Galmed Pharmaceuticals
0.7x-15.9%US$16.3m
BNTC Benitec Biopharma
1.5x-25.3%US$11.0m

Price-To-Book vs Peers: BNTC is expensive based on its Price-To-Book Ratio (1.3x) compared to the peer average (0.5x).


Price to Earnings Ratio vs Industry

How does BNTC's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BNTC is good value based on its Price-To-Book Ratio (1.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is BNTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNTC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BNTC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BNTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BNTC ($1.16) is trading below our estimate of fair value ($221.52)

Significantly Below Fair Value: BNTC is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNTC's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Benitec Biopharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNTC's revenue (84% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: BNTC's revenue (84% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BNTC's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Benitec Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BNTC is currently unprofitable.

Growing Profit Margin: BNTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNTC is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.

Accelerating Growth: Unable to compare BNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BNTC has a negative Return on Equity (-227.98%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Benitec Biopharma's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BNTC's short term assets ($8.8M) exceed its short term liabilities ($1.9M).

Long Term Liabilities: BNTC's short term assets ($8.8M) exceed its long term liabilities ($635.0K).


Debt to Equity History and Analysis

Debt Level: BNTC is debt free.

Reducing Debt: BNTC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNTC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BNTC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.9% each year


Discover healthy companies

Dividend

What is Benitec Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNTC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNTC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure


CEO

Jerel Banks (46 yo)

4yrs

Tenure

US$1,403,063

Compensation

Dr. Jerel A. Banks, Ph D., M.D. has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Inc. since O...


CEO Compensation Analysis

Compensation vs Market: Jerel's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD760.83K).

Compensation vs Earnings: Jerel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BNTC's management team is seasoned and experienced (5.9 years average tenure).


Board Members

Experienced Board: BNTC's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Benitec Biopharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Benitec Biopharma Inc.
  • Ticker: BNTC
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$9.479m
  • Shares outstanding: 8.17m
  • Website: https://benitec.com

Number of Employees


Location

  • Benitec Biopharma Inc.
  • 3940 Trust Way
  • Hayward
  • California
  • 94545
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.